Oncology

AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed the advantages of tab-cel over other T-cell therapies.

New treatment options expand management of relapsed or refractory disease.

Dan Oliver, cofounder and chief executive officer, Rejuvenate Bio, discussed the advantages of developing gene therapies for both dogs and humans.

CYNK-101 is set to be evaluated in combination with standard chemotherapy, trastuzumab and pembrolizumab in a phase 1/2a study.

The hematologist/oncologist at Moffitt Cancer Center discussed emerging therapies for patients with relapsed/refractory multiple myeloma.

CRISPR Therapeutics presented positive data on 2 preclinical programs at the 2021 SITC meeting.

The co-leader of Cancer Immunology & Immunotherapy Program, UCSF Helen Diller Family Comprehensive Cancer Center discussed he utility of CAR T-cell therapy in late relapsed multiple myeloma.

Review top news and interview highlights from the week ending November 26, 2021.

In 26 patients with LBCL followed for at least 28 days, the objective response rate (ORR) was 58% with complete responses (CRs) in 38% of patients.

The designation follows durable responses seen in a phase 1 study of the agent.

The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in a variety of cancers.

The recommended phase 2 dose of cilta-cel elicited deep and durable responses, along with a tolerable safety profile.

Positive data has been seen with CAR T-cell therapy in patients with indolent lymphoma.

Experts discussed using newer targeted treatment approaches as frontline therapy instead of transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.

Review top news and interview highlights from the week ending November 19, 2021.

Experts discussed using CD19-targeted agents in patients with various subtypes of diffuse large B-cell lymphoma.

The hematologist at Ohio State University Comprehensive Cancer Center–The James discussed utilization rates of autologous stem cell transplant in patients with mantle cell lymphoma.

AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed data from the ALLELE study to be presented at ASH 2021.

A reduction in late mortality among patients who received allogeneic blood or marrow transplantation in the last 40 years was limited to those who received treatment at a younger age.

Dan Oliver, cofounder and chief executive officer, Rejuvenate Bio, discussed the company’s ultimate goal of reversing aging.

The NK cell therapy is also being evaluated in a phase 1 study for acute myeloid leukemia.

The professor of medicine at Duke University School of Medicine previously served as commissioner in 2016.

The hematologist from Ohio State University Comprehensive Cancer Center–The James discussed the impact of socioeconomic factors on completion of autologous stem cell transplant in patients with mantle cell lymphoma.

Overall survival was 72% at 12 months but dropped to 54% at 14.6 months.

The request aims to ensure the comparability of omidubicel manufactured at different sites.

The director of Lymphoma Clinical Research at the University of Texas MD Anderson Cancer Center, discussed the future of DLBCL treatment.

A single administration of LN-145 monotherapy resulted in an overall response rate of 21.4% in patients with immunotherapy pretreated metastatic non–small cell lung cancer.

Review top news and interview highlights from the week ending November 12, 2021.

The first in-human study of CAR macrophages has dosed 2 participants so far.

The associate professor of medicine from MD Anderson Cancer Center discussed data from the phase 1 cohort of liso-cel combined with ibrutinib.